Pharmaceutical services firm Gentris Corporation has named Amelia Wall Warner the company’s new president.
Warner will oversee the company’s U.S. operations and lead the development of new service offerings among other responsibilities. Research Triangle Park-based Gentris specializes in pharmacogenomics, which involves testing how an individual’s genetic makeup influences the effect of a drug.
Warner was most recently the head of clinical pharmacogenomics and clinical specimen management for Merck Research Laboratories (MRL). There, she oversaw all clinical pharmacogenomics projects, oversaw policies and procedures for biosample collection and storage for clinical trial samples and was the MRL Pharmacogenomics Expert for the Translational Science Research Network.
Warner holds a Pharm. D. from the University of North Carolina at Chapel Hill and a bachelor’s degree in biology from Wake Forest University.
“We are pleased that Dr. Amelia Wall Warner, one of the top global leaders in biospecimen and pharmacogenomic innovation, has joined the Gentris leadership team as President,” Gentris CEO Rick Williams said in a statement. “With her extensive experience in drug development, she will play a key role in helping Gentris to further integrate clinical genomics into its scientific programs that support pharmaceutical and biotechnology companies.”
